Press Releases Avenue Therapeutics, Inc.

Equities

ATXI

US05360L4032

Real-time Estimate Cboe BZX Other stock markets 11:49:47 30/04/2024 pm IST			5-day change	1st Jan Change
4.965 ^USD	+9.97%		-52.04%	-60.08%

18/03	Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
22/02	Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds	29/04	AQ
Avenue Therapeutics Announces Reverse Stock Split	24/04	AQ
Avenue Therapeutics to Host Virtual Key Opinion Leader Event on April 4, 2024	26/03	AQ
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024	25/03	AQ
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights	19/03	AQ
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq	15/03	AQ
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting	11/03	AQ
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy	22/02	AQ
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference	11/01	AQ
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds	05/01	AQ
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol	04/01	AQ
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy	03/01	AQ
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)	02/01	AQ
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting	04/12	AQ
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting	01/12	AQ
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights	14/11	AQ
Avenue Therapeutics Announces Closing of $5.0 Million Public Offering	03/11	AQ
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering	31/23/31	AQ
Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference	05/23/05	AQ
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights	11/23/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Avenue Therapeutics, Inc.

Equities

ATXI

US05360L4032

Press Releases

Filters